Despite tumor and patient heterogeneity, as well as the gap between cell line models and clinical samples, 4 genes (8.6%) were also modulated in breast tumor samples with distinct ERBB2 backgrounds: ATP5L was increased in the ERBB2-positive samples, whereas LOX (ENSG00000113083), GALNT3 (ENSG00000115339), and MME (ENSG00000196549) showed reduced expression when ERBB2 was elevated (Figure 6E). Here, LOX is linked to breast neoplasm.